Endocrine Society updates osteoporosis Clinical Practice Guideline
WASHINGTON–The Endocrine Society today announced an update to its osteoporosis Clinical Practice Guideline to include recommendations for romosozumab, a new medication that was approved last year to treat postmenopausal women at high risk of fracture. The U.S. Food and Drug Administration approved romosozumab in April 2019, a month after the guideline was published. “We felt…
Details